Symbols / DWTX
DWTX Chart
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 89.83M |
| Enterprise Value | 36.80M | Income | -39.98M | Sales | — |
| Book/sh | -14.42 | Cash/sh | 4.42 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.44 | PEG | — |
| P/S | — | P/B | -0.19 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.90 |
| Current Ratio | 4.49 | Debt/Eq | 2.41 | LT Debt/Eq | — |
| EPS (ttm) | -25.59 | EPS next Y | -6.37 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 | ROA | -42.04% |
| ROE | -9.31% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 29.73M |
| Shs Float | 567.88K | Short Float | 0.20% | Short Ratio | 1.09 |
| Short Interest | — | 52W High | 14.69 | 52W Low | 2.60 |
| Beta | 1.92 | Avg Volume | 49.37K | Volume | 26.73K |
| Target Price | $19.00 | Recom | Strong_buy | Prev Close | $2.75 |
| Price | $2.80 | Change | 1.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.00
Mean price target
2. Current target
$2.80
Latest analyst target
3. DCF / Fair value
$-11.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.80
Low
$12.00
High
$30.00
Mean
$19.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-30 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-23 | up | HC Wainwright & Co. | Neutral → Buy | $10 |
- DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence - Stocktwits Mon, 22 Dec 2025 08
- Early trial hints at new option for chemo-related nerve pain sufferers - Stock Titan Mon, 22 Dec 2025 08
- Dogwood Therapeutics stock plummets after Phase 2b interim results - Investing.com Mon, 22 Dec 2025 08
- Dogwood Secures License To Develop Serpin Pharma's IV Formulation Of SP16 - Nasdaq Mon, 29 Sep 2025 07
- DWTX Stock Surge: Must-Know Insights - StocksToTrade Mon, 29 Sep 2025 07
- Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - Yahoo Finance Mon, 12 Jan 2026 08
- Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer P - GlobeNewswire Mon, 29 Sep 2025 07
- Why DWTX stock is popular among millennials - July 2025 Momentum & Safe Capital Growth Stock Tips - mfd.ru hu, 12 Feb 2026 10
- Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - The Globe and Mail Mon, 02 Feb 2026 08
- Bearish Setup: Will DWTX stock hit new highs in YEAR - Earnings Recap Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn hu, 19 Feb 2026 16
- Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug - Stocktwits Mon, 29 Sep 2025 07
- DWTX Stock Price and Chart — NASDAQ:DWTX - TradingView ue, 12 Nov 2024 08
- New funding backs a non-opioid drug for chemotherapy nerve pain - Stock Titan Mon, 12 Jan 2026 08
- Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - Yahoo Finance Mon, 31 Mar 2025 07
- Dogwood Therapeutics, Inc (DWTX) - Zacks Investment Research Fri, 11 Oct 2024 03
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 24453588 | — | — | SEALBOND LTD | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.25 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.22M | -5.45M | -12.32M | -15.64M |
| TotalUnusualItems | -30.79K | |||
| TotalUnusualItemsExcludingGoodwill | -30.79K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.35M | -5.30M | -12.25M | -15.96M |
| ReconciledDepreciation | 12.18K | 0.00 | ||
| EBITDA | -12.25M | -5.45M | -12.32M | -15.64M |
| EBIT | -12.26M | -5.45M | -12.32M | -15.64M |
| NetInterestIncome | -92.19K | 150.90K | 67.47K | 5.67K |
| InterestExpense | 92.19K | |||
| InterestIncome | 150.90K | 67.47K | ||
| NormalizedIncome | -12.32M | -5.30M | -12.25M | -15.96M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.35M | -5.30M | -12.25M | -15.96M |
| TotalExpenses | 12.23M | 5.45M | 12.32M | 15.64M |
| TotalOperatingIncomeAsReported | -12.23M | -5.45M | -12.32M | -15.64M |
| DilutedAverageShares | 1.03M | 751.07K | 442.80K | 333.17K |
| BasicAverageShares | 1.03M | 751.07K | 442.80K | 333.17K |
| DilutedEPS | -12.52 | -7.00 | -27.75 | -48.00 |
| BasicEPS | -12.52 | -7.00 | -27.75 | -48.00 |
| DilutedNIAvailtoComStockholders | -12.35M | -5.30M | -12.25M | -15.96M |
| NetIncomeCommonStockholders | -12.35M | -5.30M | -12.25M | -15.96M |
| NetIncome | -12.35M | -5.30M | -12.25M | -15.96M |
| NetIncomeIncludingNoncontrollingInterests | -12.35M | -5.30M | -12.25M | -15.96M |
| NetIncomeContinuousOperations | -12.35M | -5.30M | -12.25M | -15.96M |
| TaxProvision | -503.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -12.35M | -5.30M | -12.25M | -15.96M |
| OtherIncomeExpense | -30.79K | -325.00K | ||
| OtherNonOperatingIncomeExpenses | -325.00K | |||
| GainOnSaleOfSecurity | -30.79K | |||
| NetNonOperatingInterestIncomeExpense | -92.19K | 150.90K | 67.47K | 5.67K |
| TotalOtherFinanceCost | -67.47K | -5.67K | ||
| InterestExpenseNonOperating | 92.19K | |||
| InterestIncomeNonOperating | 150.90K | 67.47K | ||
| OperatingIncome | -12.23M | -5.45M | -12.32M | -15.64M |
| OperatingExpense | 12.23M | 5.45M | 12.32M | 15.64M |
| ResearchAndDevelopment | 3.53M | 1.73M | 8.07M | 10.80M |
| SellingGeneralAndAdministration | 8.70M | 3.72M | 4.25M | 4.85M |
| GeneralAndAdministrativeExpense | 8.70M | 3.72M | 4.25M | 4.85M |
| OtherGandA | 8.70M | 3.72M | 4.25M | 4.85M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 7.72K | 7.72K | ||
| OrdinarySharesNumber | 1.33M | 770.32K | 733.22K | 333.21K |
| ShareIssued | 1.34M | 778.03K | 733.22K | 333.21K |
| NetDebt | 533.13K | |||
| TotalDebt | 15.59M | 0.00 | ||
| TangibleBookValue | -87.65M | 3.81M | 7.33M | 14.50M |
| InvestedCapital | 5.26M | 3.81M | 7.33M | 14.50M |
| WorkingCapital | 13.37M | 3.81M | 7.33M | 14.50M |
| NetTangibleAssets | -13.24M | 3.81M | 7.33M | 14.50M |
| CapitalLeaseObligations | 204.58K | 0.00 | ||
| CommonStockEquity | -10.12M | 3.81M | 7.33M | 14.50M |
| PreferredStockEquity | 74.41M | |||
| TotalCapitalization | 79.66M | 3.81M | 7.33M | 14.50M |
| TotalEquityGrossMinorityInterest | 64.28M | 3.81M | 7.33M | 14.50M |
| StockholdersEquity | 64.28M | 3.81M | 7.33M | 14.50M |
| GainsLossesNotAffectingRetainedEarnings | -3.86M | 0.00 | ||
| OtherEquityAdjustments | -3.86M | |||
| TreasuryStock | 299.13K | 299.13K | 0.00 | |
| RetainedEarnings | -73.82M | -61.47M | -56.17M | -43.93M |
| AdditionalPaidInCapital | 67.86M | 65.58M | 63.50M | 58.43M |
| CapitalStock | 74.41M | 77.00 | 1.83K | 833.00 |
| CommonStock | 133.00 | 77.00 | 1.83K | 833.00 |
| PreferredStock | 74.41M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 30.03M | 358.55K | 1.04M | 1.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.85M | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 11.31M | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 11.31M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 15.54M | 0.00 | ||
| LongTermCapitalLeaseObligation | 154.88K | 0.00 | ||
| LongTermDebt | 15.38M | |||
| CurrentLiabilities | 3.18M | 358.55K | 1.04M | 1.28M |
| CurrentDebtAndCapitalLeaseObligation | 49.70K | |||
| CurrentCapitalLeaseObligation | 49.70K | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 737.28K | 0.00 | 159.70K | 532.68K |
| PayablesAndAccruedExpenses | 2.39M | 358.55K | 883.56K | 742.95K |
| CurrentAccruedExpenses | 1.16M | 246.63K | 310.39K | 389.08K |
| InterestPayable | 417.54K | 188.09K | 188.09K | 188.09K |
| Payables | 1.23M | 111.91K | 573.16K | 353.86K |
| AccountsPayable | 1.23M | 111.91K | 573.16K | 353.86K |
| TotalAssets | 94.31M | 4.17M | 8.37M | 15.78M |
| TotalNonCurrentAssets | 77.76M | 0.00 | 0.00 | 0.00 |
| NonCurrentPrepaidAssets | 18.13K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 77.52M | 0.00 | ||
| OtherIntangibleAssets | 65.71M | |||
| Goodwill | 11.81M | 0.00 | ||
| NetPPE | 222.65K | 0.00 | ||
| AccumulatedDepreciation | -1.58K | |||
| GrossPPE | 224.22K | 0.00 | ||
| OtherProperties | 205.84K | |||
| MachineryFurnitureEquipment | 18.39K | |||
| CurrentAssets | 16.54M | 4.17M | 8.37M | 15.78M |
| OtherCurrentAssets | 28.01K | 3.56K | 7.29K | 863.00 |
| PrepaidAssets | 1.67M | 844.94K | 1.33M | 1.77M |
| CashCashEquivalentsAndShortTermInvestments | 14.85M | 3.32M | 7.03M | 14.01M |
| CashAndCashEquivalents | 14.85M | 3.32M | 7.03M | 14.01M |
| CashFinancial | 14.85M | 3.32M | 7.03M | 14.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.79M | -4.87M | -11.47M | -15.69M |
| RepurchaseOfCapitalStock | -351.00 | 0.00 | -295.17K | |
| IssuanceOfDebt | 15.32M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 1.38M | 1.16M | 4.49M | |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 14.85M | 3.32M | 7.03M | 14.01M |
| BeginningCashPosition | 3.32M | 7.03M | 14.01M | 29.80M |
| EffectOfExchangeRateChanges | -144.59K | 0.00 | ||
| ChangesInCash | 11.68M | -3.71M | -6.98M | -15.79M |
| FinancingCashFlow | 16.70M | 1.16M | 4.49M | -97.60K |
| CashFlowFromContinuingFinancingActivities | 16.70M | 1.16M | 4.49M | -97.60K |
| InterestPaidCFF | 0.00 | |||
| ProceedsFromStockOptionExercised | 0.00 | 197.56K | ||
| CashDividendsPaid | 0.00 | |||
| NetCommonStockIssuance | 1.38M | 1.16M | 4.49M | -295.17K |
| CommonStockPayments | -351.00 | 0.00 | -295.17K | |
| CommonStockIssuance | 1.38M | 1.16M | 4.49M | |
| NetIssuancePaymentsOfDebt | 15.32M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 15.32M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 15.32M | 0.00 | 0.00 | |
| InvestingCashFlow | 3.76M | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | 3.76M | 0.00 | ||
| NetBusinessPurchaseAndSale | 3.76M | 0.00 | ||
| SaleOfBusiness | 3.76M | 0.00 | ||
| OperatingCashFlow | -8.79M | -4.87M | -11.47M | -15.69M |
| CashFlowFromContinuingOperatingActivities | -8.79M | -4.87M | -11.47M | -15.69M |
| ChangeInWorkingCapital | -581.27K | -194.45K | 197.38K | -52.19K |
| ChangeInPayablesAndAccruedExpense | -82.55K | -684.71K | -232.36K | 38.95K |
| ChangeInAccruedExpense | -302.44K | -223.46K | -451.66K | -231.06K |
| ChangeInPayable | 219.89K | -461.25K | 219.30K | 270.01K |
| ChangeInAccountPayable | 219.89K | -461.25K | 219.30K | 270.01K |
| ChangeInPrepaidAssets | -498.72K | 490.27K | 429.74K | -91.14K |
| OtherNonCashItems | 3.62M | |||
| StockBasedCompensation | 476.02K | 619.97K | 582.66K | 322.88K |
| ProvisionandWriteOffofAssets | 0.00 | |||
| DeferredTax | -503.00 | 0.00 | ||
| DeferredIncomeTax | -503.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 12.18K | 0.00 | ||
| DepreciationAndAmortization | 12.18K | 0.00 | ||
| Depreciation | 12.18K | 0.00 | ||
| OperatingGainsLosses | 30.79K | |||
| NetForeignCurrencyExchangeGainLoss | 30.79K | 0.00 | ||
| NetIncomeFromContinuingOperations | -12.35M | -5.30M | -12.25M | -15.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DWTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|